Table 1 Demographics and clinical characteristics of patients in the Sichuan and Wuhan cohorts
Variable | Total | Sichuan cohort | Wuhan cohort | χ2/Z | P value |
|---|---|---|---|---|---|
n | 1184 | 474 | 710 | Â | Â |
Female, n (%) | 604 (51.0) | 220 (46.4) | 384 (54.1) | 6.693 | 0.010 |
Age, years (Median [IQR]) | 50.50 (37.00,64.00) | 44.00 (32.00,54.00) | 58.00 (43.00,67.00) | 12.054 | < 0.001 |
Travel in Wuhan/residence in Wuhan/no exposure history, n | 141/869/174 | 128/177/169 | 13/692/5 | 527.493 | < 0.001 |
Health care workers, n (%) | 15 (1.3) | 2 (0.4) | 13 (1.8) | 4.532 | 0.033 |
Current/ ever/ never smoking, n | 96/42/892 | 67/18/376 | 29/24/516 | 26.843 | < 0.001 |
Any comorbidity | 574 (48.2) | 208 (43.8) | 366 (51.2) | 6.258 | 0.012 |
Charlson Comorbidity Index | 1.0 (0–2.0) | 0 (0–1.0) | 2 (2.0–3.0) | −9.190 | < 0.001 |
Disease severity status, n |  |  |  | 97.524 | < 0.001 |
 Mild/general/severe/critical | 194/725/141/127 | 28/337/81/30 | 166/388/60/97 |  |  |
CURB-65 score, n (%) | |||||
 0–1/2/3–5 | 837/68/20 | 369/12/2 | 468/56/18 | 26.430 | < 0.001 |
 MuLBSTA score (Median [IQR]) | 7.00 (5.00,9.00) | 5.00 (5.00,9.00) | 7.00 (5.00,9.00) | 3.96 | < 0.001 |
Laboratory findings, Median (IQR) | |||||
 White blood cell count, ×109 /L | 5.45 (4.22,7.07) | 5.37 (4.18,5.37) | 5.58 (4.22,7.28) | 1.570 | 0.088 |
 Neutrophil count, ×109 /L | 3.45 (2.50,4.99) | 3.45 (2.53,4.73) | 3.45 (2.47,5.26) | 2.723 | < 0.001 |
 Lymphocyte count, ×109 /L | 1.18 (0.83,1.63) | 1.18 (0.81,1.60) | 1.18 (0.84,1.64) | 1.074 | 0.157 |
 Eosinophil count, ×109 /L | 0.30 (0.00,1.30) | 0.20 (0.01,0.80) | 0.50 (0.0,1.7) | 5.751 | < 0.001 |
 Hemoglobin, g/L | 131.00 (119.00,144.00) | 137.00 (126.00,151.00) | 127.00 (117.00,137.00) | 8.049 | 0.015 |
 Platelet count, ×109 /L | 197.00 (148.00,262.50) | 175.00 (137.00,230.50) | 215.00 (165.00,281.00) | 7.909 | < 0.001 |
 Activated partial thromboplastin time, s | 28.50 (25.90,32.20) | 30.90 (27.70,34.90) | 27.40 (25.20,29.90) | 10.129 | < 0.001 |
 Prothrombin time, s | 12.20 (11.50,13.00) | 12.60 (11.70,13.30) | 12.00 (11.33,12.70) | 2.052 | 0.115 |
 D-dimer, mg/L | 0.56 (0.29,1.59) | 0.50 (0.22,1.17) | 0.63 (0.33,1.79) | 3.194 | 0.001 |
 Albumin, g/L | 39.70 (35.50,43.30) | 43.00 (39.60,45.70) | 37.70 (34.00,40.80) | 11.556 | 0.128 |
 Creatinine, μmol/L | 63.00 (51.00,76.15) | 65.20 (53.00,77.33) | 62.00 (50.70,75.00) | 2.051 | 0.040 |
 Creatine kinase, U/L | 62.70 (41.00,106.25) | 71.00 (50.00,122.00) | 56.00 (34.40,99.00) | 5.181 | < 0.001 |
 Alanine aminotransferase, U/L | 23.55 (16.00,39.05) | 24.00 (16.00,39.90) | 23.00 (15.48,39.00) | 0.433 | 0.665 |
 Aspartate aminotransferase, U/L | 25.00 (19.67,35.73) | 25.60 (20.00,35.00) | 25.00 (19.00,36.00) | 0.459 | 0.647 |
 C-reactive protein, mg/L | 19.95 (6.80,53.92) | 10.16 (2.67,24.72) | 28.45 (8.70,65.20) | 6.066 | < 0.001 |
 Procalcitonin, ng/mL | 0.05 (0.04,0.12) | 0.06 (0.04,0.17) | 0.05 (0.03,0.11) | 2.06 | 0.039 |
 Hypersensitive troponin I, pg/ml | 0.01 (0.01,0.01) | 0.01 (0.01,0.01) | 0.02 (0.01,0.05) | 3.615 | < 0.001 |
Chest CT, n (%) | |||||
 Bilateral lungs involvement | 741 (93.1) | 328 (90.6) | 413 (95.2) | 6.363 | 0.012 |
 Consolidation | 180 (19.6) | 73 (16.0) | 107 (23.2) | 7.533 | 0.006 |
 Ground-glass opacity | 666 (71.3) | 328 (71.6) | 338 (71.0) | 0.042 | 0.837 |
 Linear opacity | 257 (27.8) | 112 (24.5) | 145 (31.2) | 5.200 | 0.023 |
 Pleural effusion | 49 (5.4) | 19 (4.2) | 30 (6.6) | 2.559 | 0.110 |